High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept

American Journal of Transplantation

Volumn 14, Issue 3, 2014, Pages 607-614

  Krummey, S M ^a   Cheeseman, J A ^a   Conger, J A ^a   Jang, P S ^a   Mehta, A K ^a   Kirk, A D ^a   Larsen, C P ^a   Ford, M L ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Acute rejection; costimulation blockade; T cell memory

Indexed keywords

BELATACEPT; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR6; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ALLOIMMUNITY; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPH NODE; LYMPHOCYTE DIFFERENTIATION; MEMORY CELL; MIDDLE AGED; PRIORITY JOURNAL; TH1 CELL; TH17 CELL; UPREGULATION;

ANTIGENS, CD; CELLS, CULTURED; COHORT STUDIES; CTLA-4 ANTIGEN; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROGNOSIS; TH17 CELLS;

EID: 84896733236     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12600     Document Type: Article

References (28)

1. Sallusto F, Lanzavecchia A., Heterogeneity of CD4+ memory T cells: Functional modules for tailored immunity. Eur J Immunol 2009; 39: 2076-2082.
2. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887-1895.
3. Amir AL, D'Orsogna LJ, Roelen DL, et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010; 115: 3146-3157.
4. Falkenburg WJ, Melenhorst JJ, van de Meent M, et al. Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity. J Immunol 2011; 187: 2824-2833.
5. Felix NJ, Donermeyer DL, Horvath S, et al. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol 2007; 8: 388-397.
6. Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21: 1587-1596.
7. Ndejembi MP, Teijaro JR, Patke DS, et al. Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol 2006; 177: 7698-7706.
8. Bouguermouh S, Fortin G, Baba N, Rubio M, Sarfati M., CD28 co-stimulation down regulates Th17 development. PLoS ONE 2009; 4: e5087.
9. Ying H, Yang L, Qiao G, et al. Cutting edge: CTLA-4-B7 interaction suppresses Th17 cell differentiation. J Immunol 2010; 185: 1375-1378.
10. de Wit J, Souwer Y, van Beelen AJ, et al. CD5 costimulation induces stable Th17 development by promoting IL-23R expression and sustained STAT3 activation. Blood 2011; 118: 6107-6114.
11. Santarlasci V, Maggi L, Capone M, et al. Rarity of human T helper 17 cells is due to retinoic acid orphan receptor-dependent mechanisms that limit their expansion. Immunity 2012; 36: 201-214.
12. Paulos CM, Carpenito C, Plesa G, et al. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Transl Med 2010; 2: 55ra78.
13. Chatterjee M, Rauen T, Kis-Toth K, et al. Increased expression of SLAM receptors SLAMF3 and SLAMF6 in systemic lupus erythematosus T lymphocytes promotes Th17 differentiation. J Immunol 2012; 188: 1206-1212.
14. Miossec P, Korn T, Kuchroo VK., Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-898.
15. Zielinski CE, Mele F, Aschenbrenner D, et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 2012; 484: 514-518.
16. Korn T, Bettelli E, Oukka M, Kuchroo VK., IL-17 and Th17 cells. Annu Rev Immunol 2009; 27: 485-517.
17. Peters A, Lee Y, Kuchroo VK., The many faces of Th17 cells. Curr Opin Immunol 2011; 23: 702-706.
18. Wilke CM, Bishop K, Fox D, Zou W., Deciphering the role of Th17 cells in human disease. Trends Immunol 2011; 32: 603-611.
19. Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007; 8: 639-646.
20. Salomon B, Bluestone JA., Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225-252.
21. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 3077-3087.
22. Linsley PS, Nadler SG., The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 2009; 229: 307-321.
23. Sandborn WJ, Colombel JF, Sands BE, et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012; 143: 62-69.e4.
24. Vondran FW, Timrott K, Kollrich S, Klempnauer J, Schwinzer R, Becker T., Decreased frequency of peripheral CD4(+) CD161(+) Th(17)-precursor cells in kidney transplant recipients on long-term therapy with belatacept. Transpl Int 2012; 25: 455-463.
25. Corse E, Allison JP., Cutting edge: CTLA-4 on effector T cells inhibits in trans. J Immunol 2012; 189: 1123-1127.
26. Lu Y, Schneider H, Rudd CE., Murine regulatory T cells differ from conventional T cells in resisting the CTLA-4 reversal of TCR stop-signal. Blood 2012; 120: 4560-4570.
27. Wang CJ, Kenefeck R, Wardzinski L, et al. Cutting edge: Cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells. J Immunol 2012; 189: 1118-1122.
28. Mele DA, Salmeron A, Ghosh S, Huang HR, Bryant BM, Lora JM., BET bromodomain inhibition suppresses TH17-mediated pathology. J Exp Med 2013; 210: 2181-2190.